News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status. The lawsuit …
Capri Holdings Limited CPRI has been making constant efforts to enhance the customer experience and strengthen engagement with consumers. The company is focused on revitalizing its core brands, Michael Kors and Jimmy Choo, by strengthening brand desirability, improving product offerings and enhancing consumer connections. …
Capri Holdings Limited CPRI lowered its fiscal 2027 revenue outlook even as first-quarter profitability improved, underscoring the uneven nature of its turnaround. The company now expects revenues of about $3.4 billion, down from its previous forecast of $3.525 billion. Management is offsetting the weaker …
Capricor Therapeutics (CAPR) stock surged by 97.39% following the publication of positive Phase 3 HOPE-3 trial data in The Lancet, showing its drug deramiocel slowed upper-limb decline in Duchenne muscular dystrophy. This scientific validation, coupled with an FDA Biologics License Application (BLA) under active …
Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans …
The Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements regarding changes …
Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action date of August 22,” and framed updates around “our …
This article provides a brief "Q2 Earnings Snapshot" for Capricor. The full content of the article is not available beyond the title, indicating it may be a placeholder or an article with minimal information.
Hagens Berman is encouraging investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to come forward regarding a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements about the clinical trial data and regulatory pathway for …
Capricor Therapeutics reported a wider-than-expected Q2 2026 loss of $0.70 per share but saw its stock surge 83.6% after hours due to positive investor focus on its updated regulatory strategy for deramiocel, its Duchenne muscular dystrophy treatment. The company announced the FDA is open …
Capricor Therapeutics is facing a federal securities lawsuit alleging that the company failed to disclose crucial information regarding changes in the statistical analysis plan for Deramiocel, its lead therapy candidate. The lawsuit claims that these omissions, particularly concerning FDA interactions and data analysis, led …
Robbins Geller Rudman & Dowd LLP has announced a shareholder class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, and suffered …
(RTTNews) - Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, reported second-quarter 2026 financial results and provided business updates, highlighting accelerating enrollment in the Phase 1 ACESOT-1051 trial of APR-1051 and plans to expand the program …
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Jennifer Davis Chairman and Chief Executive Officer - John Idol Chief Financial and Chief Operating Officer - Tyler Reddien Full Conference Call …
This article announces that Aprea Therapeutics Inc. has filed a Form 8K for August 12. The brief piece includes the stock symbol APRE and notes a 1.34% increase in its value. The content primarily serves as a notice of the filing.
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made false and misleading statements and failed to …
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor Therapeutics' shares collapsed after FDA briefing documents …
Aprea Therapeutics reported its second-quarter 2026 results, showing no revenue due to exhausted NIH grant funding, a net loss of $(3.59M), and a diluted EPS of $(0.07). The company is focusing on its WEE1 inhibitor, APR-1051, which has shown early proof-of-concept in clinical trials, …
Aprea Therapeutics announced its financial results for the second quarter ended June 30, 2026, reporting $41.2 million in cash and cash equivalents and an operating loss of $4.0 million. The company is accelerating enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor …
Search by ticker symbol or company name and select a result to open its chart.